Bristol Myers Squibb - U.S. Food and Drug Administration Approve…
https://news.bms.com/news/details/2021/U.S.-Food-and-Drug-Administration-Approves-Bristol-Myers-Squibbs-Breyanzi-lisocabtagene-maraleucel-a-New-CAR-T-Cell-Therapy-for-Adults-with-Relapsed-or-Refractory-Large-B-cell-Lymphoma/default.aspx
WebFeb 5, 2021 · Juno Therapeutics, Inc. is a wholly owned subsidiary of Bristol-Myers Squibb Company. The approval of Breyanzi is based on a Biologics License Application that was submitted by …
DA: 75 PA: 43 MOZ Rank: 83